ClinicalTrials.Veeva

Menu

A Study of ResCure™ to Treat COVID-19 Infection

P

ProgenaBiome

Status and phase

Withdrawn
Phase 1

Conditions

Sars-CoV2
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Corona Virus Infection
COVID
Coronavirus-19
Covid-19
SARS Pneumonia

Treatments

Biological: ResCure™

Study type

Interventional

Funder types

Other

Identifiers

NCT04395716
PRG-048

Details and patient eligibility

About

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Full description

In this Phase I open-label interventional study we will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection. Patients being treated will have severe respiratory symptoms that are at or near requiring the patient be placed on a ventilator.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Critically ill patients with SARS from COVID-19 infection on respirators OR
  2. Patients with SARS from COVID-19 infection prior or after being placed on respirator
  3. Male or female patients 18 years of age and older

Exclusion criteria

  1. Patients less than 18 years of age

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

Treatment Group
Experimental group
Description:
This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
Treatment:
Biological: ResCure™

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems